Sibilia Jean, Gottenberg Jacques-Eric, Mariette Xavier
Service de Rhumatologie, CHU Strasbourg, Centre National de Référence des Maladies Auto-immunes Systémiques Rares, Strasbourg, France.
Joint Bone Spine. 2008 Oct;75(5):526-32. doi: 10.1016/j.jbspin.2008.02.009. Epub 2008 Jun 20.
Rituximab is a chimeric anti-CD20 monoclonal antibody targeting B cells, which play numerous pathogenic roles in rheumatoid arthritis (RA). This review summarises the results of three controlled studies using rituximab in RA and the data regarding tolerance and repeated treatment in 1053 patients included in the clinical studies. These studies demonstrated the efficacy of rituximab in patients with RA, including those who had been unresponsive or intolerant to one or more TNF inhibitor therapies. Rituximab was globally well-tolerated. The current informations on the efficacy and the tolerance of rituximab led us to propose recommendations for the screening of patients, the use of rituximab, and the follow-up of patients. A longer follow-up duration and data from off-trial patients, included in registries, are now required.
利妥昔单抗是一种靶向B细胞的嵌合抗CD20单克隆抗体，B细胞在类风湿关节炎（RA）中发挥多种致病作用。本综述总结了三项在类风湿关节炎中使用利妥昔单抗的对照研究结果，以及临床研究中纳入的1053例患者的耐受性和重复治疗数据。这些研究证明了利妥昔单抗对类风湿关节炎患者的疗效，包括那些对一种或多种肿瘤坏死因子抑制剂治疗无反应或不耐受的患者。利妥昔单抗总体耐受性良好。目前关于利妥昔单抗疗效和耐受性的信息使我们能够提出关于患者筛查、利妥昔单抗使用和患者随访的建议。现在需要更长的随访时间以及来自登记处非试验患者的数据。
